Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Majidian Eydgahi S et al. | 2015 | animal, chicken/Ross (egg), whole body | magnetic field, 50/60 Hz, also other exposures without EMF, co-exposure | - |
Mandeville R et al. | 1997 | animal, rat/Fischer 344, whole body | magnetic field, 50/60 Hz | 2–2,000 µT |
Mannerling AC et al. | 2007 | animal, chicken embryos/White Leghorn, whole body | magnetic field, 50/60 Hz, co-exposure | 0.01–0.2 mT |
Margonato V et al. | 1995 | animal, rat/Sprague-Dawley, whole body | magnetic field, 50/60 Hz | 5 µT |
Masiuk M et al. | 2008 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells), K-562 (chronic myelogenous leukemia) | magnetic field, 50/60 Hz | 10–20 mT |
Masuda H et al. | 2011 | intact cell/cell culture, rat brain membranes, C6 cells (rat glioma cell line) transfected with the human 5-HT<sub>1B</sub> receptor gene | magnetic field, low frequency, 50/60 Hz | 1.1 mT |
Mercado-Sáenz S et al. | 2023 | intact cell/cell culture, yeast (<i>Saccharomyces cerevisiae</i>)/WS8105-1C | magnetic field, signals/pulses, 50/60 Hz, co-exposure, also other exposures without EMF | - |
Milani M et al. | 2001 | intact cell/cell culture, human lymphocytes | magnetic field, 50/60 Hz | 50 µT |
Miyakoshi J et al. | 1994 | intact cell/cell culture, human leukemia cell lines (HL60RG, CCRF-CEM9), GM0637 cells (normal human fibroblast cell line), TAT2SF cells (human Louis-Bar syndrome fibroblast cell line) | magnetic field, 50/60 Hz, also other exposures without EMF | 400 mT |
Miyakoshi J et al. | 2000 | intact cell/cell culture, C3H 10T1/2 cells (derived from mouse embryo fibroblasts) | magnetic field, 50/60 Hz, co-exposure | 5–400 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.